Fig. 2

Titration of total IgG and neutralising antibodies directed against the FCV-FR4_01 strain, during the course of the study. Titration of total IgG was assessed by immunofluorescence (IF; a) while neutralising antibodies were assessed by a SN assay (b). Titrations were performed from samples collected on days 0, 21, 42, 49 (DCP 0) and 63 (DCP 14) in group 1 (Leucofeligen™ FeLV/RCP, blue, n = 10), group 2 (Purevax™ RCP FeLV, green, n = 10) and group 3 (control, black, n = 9). Mean values (and SD as error bars) are reported. a A value of 0 was attributed to titration <2.1 log 10 (positive threshold) and 3.9 log 10 was the maximum value which could be measured. In the vaccinated groups, all values from day 21 were significantly different from day 0 and from values in control group (p < 0.05, Tukey adjusted multiple comparisons). a, b and c: statistically significant difference between group 1 (Leucofeligen™ FeLV/RCP) and control (a); between group 2 (Purevax™ RCP FeLV) and control (b); and between group 1 (Leucofeligen™ FeLV/RCP) and group 2 (Purevax™ RCP FeLV) (c). * p < 0.05; ** p < 0.01; *** p < 0.001. b A value of 0 was attributed to titration <0.9 log 10 (positive threshold) and 2.56 log 10 was the maximum value. No difference between groups was observed